These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil. Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735 [TBL] [Abstract][Full Text] [Related]
5. Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic. Bojadzieva J; Amini B; Day SF; Jackson TL; Thomas PS; Willis BJ; Throckmorton WR; Daw NC; Bevers TB; Strong LC Fam Cancer; 2018 Apr; 17(2):287-294. PubMed ID: 28988289 [TBL] [Abstract][Full Text] [Related]
6. Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. Gatidis S; Schmidt H; Gücke B; Bezrukov I; Seitz G; Ebinger M; Reimold M; Pfannenberg CA; Nikolaou K; Schwenzer NF; Schäfer JF Invest Radiol; 2016 Jan; 51(1):7-14. PubMed ID: 26309185 [TBL] [Abstract][Full Text] [Related]
7. Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort. Mai PL; Khincha PP; Loud JT; DeCastro RM; Bremer RC; Peters JA; Liu CY; Bluemke DA; Malayeri AA; Savage SA JAMA Oncol; 2017 Dec; 3(12):1640-1645. PubMed ID: 28772286 [TBL] [Abstract][Full Text] [Related]
8. [Li-Fraumeni syndrome - a proposal of complex prevention care for carriers of TP53 mutation with total-body MRI]. Foretová L; Stěrba J; Opletal P; Mach V; Lisý J; Petráková K; Palácová M; Navrátilová M; Gaillyová R; Puchmajerová A; Křepelová A; Macháčková E Klin Onkol; 2012; 25 Suppl():S49-54. PubMed ID: 22920207 [TBL] [Abstract][Full Text] [Related]
10. Association of germline or somatic TP53 missense mutation with oncogene amplification in tumors developed in patients with Li-Fraumeni or Li-Fraumeni-like syndrome. Sugawara W; Arai Y; Kasai F; Fujiwara Y; Haruta M; Hosaka R; Nishida K; Kurosumi M; Kobayashi Y; Akagi K; Kaneko Y Genes Chromosomes Cancer; 2011 Jul; 50(7):535-45. PubMed ID: 21484931 [TBL] [Abstract][Full Text] [Related]
11. Pediatric cancer and Li-Fraumeni/Li-Fraumeni-like syndromes: a review for the pediatrician. Giacomazzi CR; Giacomazzi J; Netto CB; Santos-Silva P; Selistre SG; Maia AL; Oliveira VZ; Camey SA; Goldim JR; Ashton-Prolla P Rev Assoc Med Bras (1992); 2015; 61(3):282-9. PubMed ID: 26248253 [TBL] [Abstract][Full Text] [Related]
12. The first pancreatic neuroendocrine tumor in Li-Fraumeni syndrome: a case report. Aversa JG; De Abreu FB; Yano S; Xi L; Hadley DW; Manoli I; Raffeld M; Sadowski SM; Nilubol N BMC Cancer; 2020 Mar; 20(1):256. PubMed ID: 32228502 [TBL] [Abstract][Full Text] [Related]
13. The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations. Finkova A; Vazna A; Hrachovina O; Bendova S; Prochazkova K; Sedlacek Z Cancer Genet Cytogenet; 2009 Aug; 193(1):63-6. PubMed ID: 19602465 [TBL] [Abstract][Full Text] [Related]
14. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Villani A; Tabori U; Schiffman J; Shlien A; Beyene J; Druker H; Novokmet A; Finlay J; Malkin D Lancet Oncol; 2011 Jun; 12(6):559-67. PubMed ID: 21601526 [TBL] [Abstract][Full Text] [Related]
15. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Villani A; Shore A; Wasserman JD; Stephens D; Kim RH; Druker H; Gallinger B; Naumer A; Kohlmann W; Novokmet A; Tabori U; Tijerin M; Greer ML; Finlay JL; Schiffman JD; Malkin D Lancet Oncol; 2016 Sep; 17(9):1295-305. PubMed ID: 27501770 [TBL] [Abstract][Full Text] [Related]
16. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Olivier M; Goldgar DE; Sodha N; Ohgaki H; Kleihues P; Hainaut P; Eeles RA Cancer Res; 2003 Oct; 63(20):6643-50. PubMed ID: 14583457 [TBL] [Abstract][Full Text] [Related]
18. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study. Klenk C; Gawande R; Uslu L; Khurana A; Qiu D; Quon A; Donig J; Rosenberg J; Luna-Fineman S; Moseley M; Daldrup-Link HE Lancet Oncol; 2014 Mar; 15(3):275-85. PubMed ID: 24559803 [TBL] [Abstract][Full Text] [Related]
19. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors. Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY Oral Oncol; 2009 Mar; 45(3):218-24. PubMed ID: 18804404 [TBL] [Abstract][Full Text] [Related]
20. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site. Pelosi E; Pennone M; Deandreis D; Douroukas A; Mancini M; Bisi G Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):15-22. PubMed ID: 16557200 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]